AstraZeneca/LinkedIn
Nov 10, 2024, 17:15
Harnessing the power of genomic insights – AstraZeneca
AstraZeneca shared a post on LinkedIn:
Together with Alexion Pharmaceuticals, Inc., we are uniquely positioned to harness the power of genomic insights. Our goal is to advance gene editing technology to unlock new possibilities for managing genetic diseases.
Our recent research published in Nature Portfolio demonstrates our progress in refining CRISPR gene editing technology, improving its precision and reliability in editing the DNA sequence.
Click here to discover more about how we are engineering the future of gene editing.”
Engineered PsCas9 enables therapeutic genome editing in mouse liver with lipid nanoparticles
Authors: Dmitrii Degtev, et al.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 11:52
Nov 13, 2024, 11:48
Nov 13, 2024, 11:44
Nov 13, 2024, 11:39
Nov 13, 2024, 11:30
Nov 13, 2024, 11:25
Nov 13, 2024, 11:10
Nov 13, 2024, 10:59
Nov 13, 2024, 10:54